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Abstract
Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells
from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the
development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique
small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope
32P, bind with vastly
differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these
peptides permanently transfers the
32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is
more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the
only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker
CD20 for the treatment of non-Hodgkin’s lymphoma. By using the method described herein, large numbers of different
32P-
labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the
development and use of
32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of
colon adenocarcinoma patients.
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Introduction
Recent landmark discoveries have convincingly documented the
extensive genetic heterogeneity among human cancers, particu-
larly colorectal tumors, by establishing the existence of a small
number of frequently mutated gene ‘‘mountains’’ and a much
higher number of gene ‘‘hills’’ mutated at much lower frequencies
[1,2]. This high degree of diversity among human colorectal
cancers suggests that individualized treatment strategies hold great
promise in successful clinical intervention. Several anticancer
immunotherapies are currently in use, including Herceptin,
Rituxin, and Avastin, a monoclonal antibody directed against
VEGF (vascular endothelial growth factor) that is approved for
colorectal cancer treatment [3–9].
Radioimmunotherapy (RIT) is an emerging technology with
thus far only two FDA-approved protocols, both directed against
non-Hodgkin’s lymphoma (NHL). Each protocol utilizes a
monoclonal antibody directed against the CD20 B-cell marker
and can deliver
90Y (Zevalin) or
131I (Bexxar), each of which
generates electrons (beta particles) that damage DNA, resulting in
cell death [10,11]. Currently, no RIT has yet been approved for
the treatment of colorectal cancer [12].
We recently reported a set of nine different decapeptides, each
varying from the others by only one to three amino acids, which
when labeled with the beta-emitter
32P, bound to and permanently
delivered, to varying degrees, this radioisotope to cell lines derived
from a panel of different colorectal adenocarcinomas [13]. The
most efficient
32P-labeled decapeptide resulted in permanent
incorporation of radioisotope into colon adenocarcinoma cellular
proteins at a rate over 100 times greater than in cell lines derived
from a variety of other cancers or from normal colon, kidney or
esophagus.
Herein, we report a class of slightly larger peptides (up to 34
amino acids long) that contain widely disparate peptide sequences,
resulting in a broad range of cellular binding and radioisotope
uptake properties. Each 34 amino acid peptide contains a nine
amino acid core at its amino end to enable
32P labeling by protein
kinase A, an eight amino acid core at its carboxy end, and up to 17
additional amino acids that dramatically alter both its binding to
cells and its permanent incorporation of radioisotope into colon
cancer cellular proteins. These results support further exploration
of this strategy to develop potential new individualized therapeutic
regimens against colon cancers.
Results
Production of
32P-labeled peptides and binding to colon
adenocarcinoma cells
Previously, we reported the discovery of nine different
32P-
labeled decapeptides, each varying from one another by only one
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bind to and transfer radioisotope permanently to proteins in cell
lines established from a panel of colon adenocarcinomas. The
most efficient of these
32P-labeled decapeptides permanently
delivered radioisotope to colon cancer cells more than 100 times
more efficiently than to cell lines derived from other cancers or the
normal tissues tested. Herein, we report the production and
identification of a new series of peptides, up to 34 amino acids in
length, whose amino acid sequences dramatically alter their ability
to bind to and permanently facilitate
32P incorporation into cells.
Figure 1 is a schematic representation of the experimental design,
illustrating the cloning of a DNA fragment containing 17
randomly generated codons into the BamHI restriction enzyme
site of pGEX-2TK. After bacterial transformation, individual
clones were selected and expanded to produce a diverse set of
32P-
labeled peptides. If no stop codons were present in the random
DNA sequence, then a 34-residue peptide was generated, flanked
at its amino end by the 9-residue protein kinase A labeling motif
and at its carboxy terminus by an 8-residue sequence. As expected,
in several clones, a stop codon was inserted, resulting in truncated
peptides; however, all of these truncated peptides contained the
protein kinase A substrate moiety. These diverse peptides were
incubated with several different cell lines for two hours, adherent
cells were washed three times, and radioactivity remaining bound
to cells was assayed either immediately, or following overnight
incubation in complete medium.
Figure 2 shows the dramatic variation in levels of permanent
32P incorporation into the colon adenocarcinoma line Caco2 after
washing and overnight medium incubation. We previously showed
that cells successfully binding decapeptides after two hours of
incubation released up to 88% of their initially bound
32P into
media after overnight incubation, but still permanently incorpo-
rated high levels of radioisotope into their proteins. The nineteen
different peptides in Figure 2 are designated MA (Modified
Adjuvant) 10 through 28. Eleven of these 19 contain complete 17-
residue inserts, with MA18 permanently transferring
32P to Caco2
cells over 37 times more efficiently than MA26. The most efficient
permanent radioisotope incorporation into Caco2 cells occurred
after incubation with MA27, which contains only one randomly
inserted amino acid upstream of a stop codon. Peptides MA16 and
MA17 were encoded by the original recombinant expression
vector, leading to low levels of radioisotope incorporation.
Visualization of
32P incorporation by gel autoradiography
Four peptides showing average levels of radioisotope incorpo-
ration were selected for further study; triplicate-well assays of these
peptides are displayed in Figure 3. Peptide MA11’s insert
contained three residues upstream of a stop codon, resulting in a
peptide only 12 amino acids in length. Despite its relatively short
length, this truncated peptide transferred
32P to Caco2 cells 215
times more efficiently than to the cervical tumor derived cell line
HeLa at two hours. After washing and overnight incubation in
medium, radioactivity retained by Caco2 cells was more than 150
times greater than that retained by HeLa cells. As shown in
Figure 3, most
32P bound to Caco2 cells was present in a low-
molecular weight (LMW) component (bold arrow) at 2 hours, but at
24 hours most of this radioactivity had been incorporated into
several different cellular proteins.
Similar results were observed for peptides MA15 and MA22,
both of which contained 17-residue inserts for a total length of 34
amino acids, and both of which incorporated 23 times more
32P
into Caco2 cells than into HeLa cells after overnight incubation
(Figure 3). Once again, both MA15 and MA22 showed an
intensely radioactive LMW band (bold arrow) at 2 hours that had
almost completely disappeared at 24 hours, with incorporation of
the remaining
32P into cellular proteins. Originally, we assumed
that this LMW band seen at 2 hours (bold arrow) represented intact
bound
32P-labeled peptide. However, the 34 amino acid peptides
MA15 and MA22 identified these intact 34-aa peptide precursors
as distinct from the intense smaller MW band (bold arrows). Thus,
we concluded that the smaller band was a rapidly processed small
intermediate molecule, which diminished greatly over the ensuring
24 hours during which the
32P was being incorporated into the
cellular proteins.
Peptide MA20 also contained a 17-residue insert. This peptide
was especially noteworthy, since it was the only one tested that was
Figure 1. Schematic diagram of experimental approach. A PCR product containing 17 random codons was inserted into the BamHI site of
pGEX-2TK producing various glutathione-S-transferase fusion proteins which were bound to glutathione-sepharose, and labeled with
32P using
protein kinase A. After washing and thrombin digestion, the labeled peptides were incubated with several different cell lines and assayed.
doi:10.1371/journal.pone.0002508.g001
32P-Labeled Peptides
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2508able to bind to a cell line not derived from colon adenocarcinomas
and provided key evidence suggesting a possible cellular processing
mechanism. As shown in Figure 3, MA20 bound at high levels to
both Caco2 and to HeLa cells at two hours. However, the LMW
band (bold arrow) seen with the other three peptides in Figure 3
was only visible with Caco2 cells, but not with HeLa cells. After
washing and overnight incubation, Caco2 cells appeared to have
processed the LMW intermediate band (bold arrow) into cellular
proteins, while HeLa cells apparently lacked the ability to
complete this next step (i.e., no radioactive cellular proteins at
these MWs were visualized, and all HeLa bound radioactivity was
still at the same molecular weight as the originally bound
32P-
labeled peptide (thin arrow)). The two bands (thin arrows, first lane of
MA20 and MA22 gels) were the result of incubation of
32P-labeled
peptide in medium containing serum for two hours at 37uC, and
demonstrated apparent partial proteolysis of the peptide during
that time.
Only colon adenocarcinoma cells process bound
radioactivity into cellular proteins
Figure 4 displays the results of incubating peptides MA11,
MA20 and MA22 with seven different carcinoma cell lines at
2 hours and after overnight incubation. Peptides MA11 and
MA22 exhibited strong binding and transfer of
32P only to the
three colon adenocarcinoma lines (Caco2, HCT116, and HCT15)
and not to cervical (HeLa), fibrosarcoma (1080), pancreatic or lung
adenocarcinoma cells. MA20, in contrast, bound avidly to all
seven cell lines, but its radioactivity was processed into the LMW
band (bold arrow) and later into cellular proteins only by the three
colon adenocarcinoma lines (Caco2, HCT116, and HCT15).
HCT116 cells consistently bound, as well as processed into larger-
MW bands, radioactivity from all three
32P-labeled peptides
(MA11, MA20, and MA22) at a much lower rate than Caco2 and
HCT15 cells, but incorporation into HCT116 cellular proteins
was eventually visible on longer exposures (data not shown).
Non-phosphorylated peptide competes with
32P-labeled
peptide for binding to Caco2 cells
The 12-aa peptide MA11 was chemically synthesized, labeled
with
32P, and used in a competitive binding assay with Caco2 cells
against varying amounts of cold, non-phosphorylated MA11
peptide. Figure 5 illustrates that phosphorylation of this peptide
was not required to successfully compete for binding to Caco2
cells, and that increasing amounts of cold competitor rapidly
inhibited the amount of
32P-labeled peptide that bound to cells.
Discussion
Nineteen different small peptides up to 34 amino acids in length
have been recombinantly produced, each containing an insert up to
17 residues long, which can be labeled at a conserved nine amino
acid substrate using
32P and protein kinase A. These
32P-labeled
peptides bind with unique affinities to cell lines established from
different colon adenocarcinomas and permanently transfer radio-
isotope to cellular proteins after two hours of incubation. The most
efficiently binding peptide results in the permanent uptake of
32Pb y
colon cancer cells over 150 times higher than by cell lines derived
from other cancers or normal tissues. In addition, one
32P-labeled
peptide bound to all cell lines tested, but
32P was processed and
permanently incorporated only by cell lines derived from colon
adenocarcinomas, implying that only this type of cancer cell
possesses the machinery necessary for this processing step. The
nineteen different peptides shown in Figure 2 were selected from an
initial screening panel containingonly 25 peptides. This surprisingly
high rate of obtaining successful peptides enhances the likelihood
that this strategy for individualized therapy development will be
feasible. Finally, a competitive binding assay using cold and
32P-
labeled synthetic MA11 peptide demonstrated that non-phosphor-
ylated peptide competes very efficiently for binding to Caco2 cells.
Most currently approved cancer immunotherapeutic regimens
use an antibody directed against a known cellular molecule and
Figure 2. Levels of binding of various
32P-labeled peptides to Caco2 cells. Different
32P-labeled peptides were incubated for two hours with
10,000 Caco2 cells, washed three times, and incubated in complete medium for 24 hours. The amount of
32P radioisotope that remained
permanently incorporated into cellular proteins is shown as a percentage of uptake of the amount of peptide added to each cell culture well (mean
plus one standard deviation). The number of amino acids present in each insert is shown and ranged from 0 to 17 amino acids. The amino acid
sequence of each insert is shown beneath the level of
32P incorporation attributed to each insert.
doi:10.1371/journal.pone.0002508.g002
32P-Labeled Peptides
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radioisotope or a toxin [14–18]. Only two radioimmunother-
apeutic (RIT) treatments are presently FDA-approved; both are
directed against non-Hodgkin’s lymphoma utilizing
131I (Bexxar)
or
90Y (Zevalin) via the cell-killing activity of emitted electrons.
32P
radioisotope is a pure beta emitter, and as shown in Table 1,i t
has many properties that compare favorably to
131I and
90Y, in
addition to being readily available and relatively inexpensive. One
advantage of using beta particles to kill tumor cells is that their
path range of up to 5 mm results in a large number of cells being
penetrated by each electron, leading to a cumulative ‘‘bystander
effect’’ due to crossfire from neighboring labeled cells.
A very active area of biomedical research focuses on the
coupling of radioisotope to peptides, as well as its use in diagnostic
and therapeutic applications [19–22]. Our proposed application of
32P-labeled small peptides in peptide binding therapy suggests a
number of advantages over traditional RIT based on monoclonal
antibodies. For example, smaller therapeutic molecules are
expected to provide better tumor penetration, and the average
small peptide molecular weight of less than 4,000 Da is less than
3% of the size of an antibody molecule [23]. Radioactive halogens
such as
131I can be processed and released prematurely by cells,
while the
32P delivered by these small peptides is permanently
incorporated into cancer cell proteins [24]. A small peptide is less
likely to incite the type of host anti-protein response that can
develop when using the much larger antibodies, and the absence
of an Fc immunoglobulin fragment should result in less nonspecific
binding by the liver. The radioisotope
32P has a long history of
clinical use dating to the early 1930’s, while today it is still used to
treat polycythemia and essential thrombocythemia [25]. There is a
Figure 3. SDS-polyacrylamide gels of
32P-peptide binding and radioisotope uptake by Caco2 cells. Four of the MA (Modified Adjuvant)
32P-peptides shown in Figure 2 were incubated with triplicate wells of Caco2 or HeLa cells for two hours. After washing, 100 ml of gel loading buffer
was added and the contents were run on SDS-polyacrylamide gels (designated as ‘‘2 hours’’). Identical wells had complete medium added
immediately after the washing step and were incubated for an additional 24 hours, and the well contents were then run on gels (designated as
‘‘24 hours’’). Film was developed after an overnight exposure showing the apparent permanent incorporation of
32P into cellular proteins at 24 hours
(marked by * in the MA11 panel). Peptide MA11 bound 215 times more avidly to Caco2 cells than to HeLa cells at two hours, and 150 times more
avidly at 24 hours. Peptide MA20 bound well to both Caco2 and HeLa cells at two hours, but only Caco2 cells appeared to possess the cellular
machinery needed to incorporate
32P into cellular proteins. The thin arrow shows the position of the
32P-labeled peptide, while the bold arrow shows
the position of a relatively low molecular weight labeled intermediate that was not seen in the HeLa cells.
doi:10.1371/journal.pone.0002508.g003
32P-Labeled Peptides
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colorectal cancer [26]. Our work suggests that an extremely large
library of different small peptides, each with unique binding and
32P transfer abilities, can be readily produced either chemically or
biologically, thus increasing the feasibility of developing individ-
ualized treatment regimens for different patients. Cancer has been
shown to be a highly heterogeneous disease, thus the development
of these unique peptide binding therapies could greatly facilitate
individualized patient treatments.
Materials and Methods
Production of the recombinant
32P-labeled peptides
As described in Figure 1, PCR generated products consisting of
17 random codons flanked by BamHI sites were cloned into the
BamHI site of pGEX-2TK (GE Healthcare). After transformation
into DH5a bacteria, isolated clones were grown overnight in LB-
amp broth, diluted 1/10 in same, grown for two hours, IPTG
added to 1 mM, and grown at 37uC for five hours. Ten ml of
culture were centrifuged and resuspended in 1 ml of 16TBS
containing 100 mg/ml lysozyme. After two freeze-thaw cycles, the
lysate was centrifuged and mixed with 100 ml Sepharose-
Glutathione for one hour, washed three times with 16TBS, and
the bound recombinant fusion proteins labeled using
32P-c-ATP
and protein kinase A according to the manufacturer’s instructions
(Sigma, St. Louis, Mo.). The pellet was washed three times with
16PBS and the labeled peptide was cleaved and released into the
supernatant using thrombin (GE Healthcare). For each recombi-
nant peptide produced and assayed, the DNA sequence of the
insert in the expression plasmid was determined.
Assay of the binding of
32P-labeled peptides to cell lines
Cell lines were grown in complete medium containing 10% heat
inactivated bovine fetal serum. In each well of a 96-well plate,
10,000 cells from various cell lines were grown overnight. Ten ml
of the
32P-labeled peptide in 16PBS and 90 ml complete medium
were added to each well and incubated at 37uC for two hours. The
peptide-medium was removed and one ml added to 100 ml gel
loading buffer for scintillation counting for the probe quantitation
Figure 4. Peptide MA20 binds to multiple cell lines, but
32P incorporation is only by colon adenocarcinoma derived lines. The
32P-
labeled peptides MA11, MA20 and MA22 were incubated with seven different cell lines as described in Figure 3. MA11 and MA22 bound to and had
32P radioisotope permanently incorporated by the three colon adenocarcinoma derived cell lines. MA20 significantly bound to all seven cell lines,
including one derived from a pancreatic adenocarcinoma and one derived from a lung adenocarcinoma, but had significant levels of
32P permanently
incorporated into cellular proteins only by the three colon adenocarcinomas. The thin arrow shows the position of the
32P-labeled peptide, while the
bold arrow indicates the position of a relatively low molecular weight labeled intermediate that was only seen in colon adenocarcinoma cells.
doi:10.1371/journal.pone.0002508.g004
Figure 5. Non-phosphorylated peptide effectively competes
with
32P-labeled MA11 peptide in binding to Caco2 cells. Into
each well containing Caco2 cells was added 0.005 mg
32P-labeled MA11
peptide and the indicated quantity of cold, non-phosphorylated MA11.
After one hour of incubation, adherent cells were washed and the
bound radioactive counts determined.
doi:10.1371/journal.pone.0002508.g005
Table 1. Comparison of Properties of Radioactive Beta
Emitting Radioisotopes.
Radioisotope Emits
Maximum beta
Energy (MeV) Range
Half-life
(days)
131Iodine Beta 0.6 1.6 mm. (avg.) 8
90Yttrium Beta 2.3 5 mm. (avg.) 2.7
32P Beta 1.7 Up to 5 mm. 14.3
Bexxar (
131I-anti-CD20) and Zevalin (
90Y-anti-CD20) are FDA-approved for the
treatment of non-Hodgkin’s lymphoma.
doi:10.1371/journal.pone.0002508.t001
32P-Labeled Peptides
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adherent cells were briefly and gently washed with complete
medium three times and some wells were assayed immediately by
adding 100 ml of gel loading buffer to each well and run on a gel or
counted in a scintillation counter. Other identically treated wells
had 200 ml complete medium added and incubated at 37uC for an
additional 24 hours. The medium was removed and 100 ml gel
loading buffer added and the samples run on a gel or counted as
described above.
Production of synthetic
32P-labeled peptide
The 12 amino acid peptide MA11 was chemically synthesized
and 0.2 mg was labeled as described above using 300 mCi of
32P-c-
ATP and 30 units of protein kinase A. After a five hour labeling
reaction, the mixture was microfuged though a Microcon-10 unit
to remove the enzyme from subsequent binding assays. For the
competitive binding assay, 0.005 mgo f
32P-labeled peptide MA11
was added to a well containing 10,000 Caco2 cells and a
designated quantity of cold, non-phosphorylated MA11. After
incubation for one hour, the adherent cells were gently washed
and the well contents counted.
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